The peer-reviewed article, authored by European investigators involved in the pivotal OCEAN and HORIZON studies, describes three heavily pretreated patients who achieved unusually durable responses – including complete and stringent complete responses lasting more than four years – while receiving melflufen plus dexamethasone.

“These exceptional cases illustrate that melflufen can induce deep and durable remissions in selected patients, even in the context of advanced disease,” says Dr. Elena Zamagni, first author of the publication and Associate Professor at the University of Bologna, Italy. “Although such long-term outcomes are rare, they highlight the drug’s potential role as a meaningful option in the modern myeloma treatment landscape.”

“These data complement the clinical evidence base from the OCEAN and HORIZON studies and underscore Pepaxti’s relevance for patients who may not be eligible for, or have access to, novel immunotherapies,” says Stefan Norin, Chief Medical Officer at Oncopeptides. “While these are individual observations, they demonstrate that Pepaxti can deliver sustained benefit and durable remission in real-world settings for certain patients.”

The article, “Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies”, is available online.

For more information, please visit oncopeptides.com, where you will also find a Q&A for investors.